Multifunctional Cu-DEOD porous polymeric nanocomposite for broad-spectrum biomedical applications

  • RSC Adv. 2026 Jan 2;16(1):657-666. doi: 10.1039/d5ra08371k.
Hadil Faris Alotaibi  1 ,  Fadhil Faez Sead  2 ,  Farag M A Altalbawy  3 ,  Nawfal Yousif  4 ,  Ahmed Salih Sahib  5  6 ,  Zahraa Saad Abdulali  7 ,  Mariem Alwan  8 ,  Mahmood Jasem  9 ,  Hiba Mushtaq  10 ,  Adama Faye  11 ,  Aseel Smerat  12
Affiliations
  • 1. Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint AbdulRahman University Riyadh 11671 Saudi Arabia.
  • 2. Department of Dentistry, College of Dentistry, The Islamic University Najaf Iraq.
  • 3. Department of Chemistry, University College of Duba, University of Tabuk Tabuk Saudi Arabia.
  • 4. Department of Radiology Techniques, Health and Medical Techniques College, Alnoor University Nineveh Iraq.
  • 5. College of Pharmacy, Ahl Al Bayt University Iraq.
  • 6. Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala Iraq.
  • 7. College of Health and Medical Technology, National University of Science and Technology Dhi Qar 64001 Iraq.
  • 8. Pharmacy College, Al-Farahidi University Iraq.
  • 9. Department of Pharmacy, Al-Zahrawi University College Karbala Iraq.
  • 10. Gilgamesh Ahliya University Baghdad Iraq.
  • 11. Department of Pharmacy, Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Ziguinchor Ziguinchor Senegal [email protected].
  • 12. Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University Amman 19328 Jordan.
PMID: 41488521 DOI: 10.1039/d5ra08371k
Abstract

A novel porous polymeric (PPN) was engineered by integrating Dabrafenib, Enrofloxacin, Dipicolinic acid, Oxidized Pectin, and copper (Cu-DEOD PPN), resulting in a porous polymeric architecture with enhanced bioactivity. The synergistic combination of therapeutic and antimicrobial agents within a stable, biocompatible matrix endowed the nanocomposite with multifunctional properties, including Anticancer, Antibacterial, antioxidant, and analgesic effects. Structural characterization confirmed uniform dispersion of active constituents and a well-defined porous network. Key findings demonstrated an average particle size of 90 nm, and biological evaluation demonstrated significant efficacy: minimum inhibitory concentration (MIC) 2-8 µg mL-1, minimum bactericidal concentration (MBC) 4-16 µg mL-1, and half-maximal inhibitory concentration (IC50) 165 µg mL-1 against NCI-H1299, and and up to 86% DPPH radical inhibition. The multifunctional performance of Cu-DEOD PPN highlights its potential as a versatile therapeutic platform for oncology, Infection management, oxidative stress mitigation, and pain relief, providing a framework for the design of next-generation bioactive nanomaterials. This study emphasizes a strategic approach to developing multifunctional nanocomposites that simultaneously combine therapeutic potency, biocompatibility, and structural integrity, offering promising applications in pharmaceutical and biomedical research.

Products